LOS ANGELES, April 1, 2008 /PRNewswire/ -- Vista Partners announced today that it has updated its coverage on American Bio Medica Corporation (Nasdaq: ABMC) and maintains its twelve month target price of $3.20. Ross Silver, Director of Research at Vista Partners stated, "Sales internationally continue to increase and sales from ABMC's lab alliance, which give ABMC's products exposure in numerous testing centers, continue to increase as well. Once the company receives CLIA approval from the FDA, we believe ABMC's valuation will increase dramatically."
About Vista Partners:
Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.
About American Bio Medica:
American Bio Medica Corporation is a biotechnology company that
develops, manufactures and markets accurate, cost-effective immunoassay
diagnostic test kits, including some of the world's most effective point of
collection tests for drugs of abuse. The Company and its worldwide
distribution network target the workplace, government, corrections,
clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid
One(R), Rapid TEC(R), RDS(R) InCup(R), Rapid TOX(R) and Rapid TOX Cup(TM)
products test for the presence or absence of drugs of abuse in urine, while
OralStat(R) and Rapid STAT(TM) tests for the presence or absence of drugs
of abuse in oral fluids. ABMC's Rapid Reader(R) is a compact, portable
device that, when connected to any computer, interprets the results of an
ABMC drug screen, and sends the results to a data management system,
enabling the test administrator to easily manage their drug testing
Vista Partners LLC
|SOURCE Vista Partners LLC|
Copyright©2008 PR Newswire.
All rights reserved